← Back to Search

Small Molecule

TGR-1202 for Chronic Lymphocytic Leukemia

Phase 2
Waitlist Available
Research Sponsored by TG Therapeutics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up evaluated at each planned visit through study completion, an average of 2 years
Awards & highlights

Study Summary

This trial is for people with B-cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia who are already receiving treatment with Ublituximab and/or TGR-1202.

Eligible Conditions
  • Chronic Lymphocytic Leukemia
  • Non-Hodgkin's Lymphoma

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~evaluated at each planned visit through study completion, an average of 2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and evaluated at each planned visit through study completion, an average of 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Adverse Events of TGR-1202 and/or TGR-1202 + ublituximab treatment, including delayed toxicities
Secondary outcome measures
Progression-free survival of TGR-1202 and/or TGR-1202 + ublituximab treatment

Trial Design

2Treatment groups
Experimental Treatment
Group I: TGR-1202 + UblituximabExperimental Treatment1 Intervention
Oral TGR-1202 in combination with Ublituximab intravenous administration
Group II: TGR-1202Experimental Treatment1 Intervention
Oral TGR-1202 Daily
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
TGR-1202
2015
Completed Phase 3
~810

Find a Location

Who is running the clinical trial?

TG Therapeutics, Inc.Lead Sponsor
36 Previous Clinical Trials
5,580 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Extension Trial of Ublituximab and TGR-1202 in Combination or as Single Agents in Subjects Currently Receiving Treatment on Ublituximab and/or TGR-1202 Trials
2017. "Extension Trial of Ublituximab and TGR-1202 in Combination or as Single Agents in Subjects Currently Receiving Treatment on Ublituximab and/or TGR-1202 Trials". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03207256.
~7 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top